Pfizer to axe 2,200 sales jobs in realignment

Blaming an onslaught of cheap generic drugs, Pfizer has announced it is cutting its sales force by 2,200, or one in five, in the U.S. For Pfizer CEO Jeff Kindler, it's all part of an ongoing realignment aimed at making the giant pharma company more agile. But it also reflects Pfizer's inability to deliver a group of new blockbusters as well as the rising resistance by physicians to spending time with a drug sales rep. Analysts quickly applauded the move and predicted that other drug companies may follow Pfizer's lead here. Without the same competition from Pfizer on the ground, analysts speculate, competitors will feel less threatened.

- check out Pfizer's press release announcing the cuts
- here's a report on Pfizer from The Chicago Tribune

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.